Moberg Pharma Q4’2024: All eyes on the European market - Redeye

Redeye views the Q4 report as uneventful in many respects, as most of the events were communicated during the quarter. The plan to launch in the EU is the same, and the path to the US is not closed, but it will take time, and the conditions have to be right. We add Norway and deduct S. Korea from our estimates. We must get further insight into how the EU market strategy will pan out during 2025 to make more significant changes. The current changes to our estimates increase our Base case to SEK 11 (9.5) per share. Following this report, we are changing the head analyst.

Länk till analysen i sin helhet: https://www.redeye.se/research/1074774/moberg-pharma-q42024-all-eyes-on-the-european-market?utm_source=finwire&utm_medium=RSS